Scientific Advisory Board

The Scientific Advisory Board (SAB) of CurePSP, advises the Board of Directors on scientific and medical matters, assists with the educational and research activities of the organization, and reviews research grant applications/proposals on a semi-annual basis. Voting members of the Scientific Advisory Board are prominent scientists and clinicians with expertise pertinent to PSP and CBD genetics, pathology, pathophysiology, clinical manifestations, and management.

Lawrence I. Golbe, MD (Chair)
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

Kristophe Diaz, PhD (Ex Officio)
Chief Executive Officer, CurePSP

Edward A. Burton, MD, DPhil, FRCP
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Ted M. Dawson, MD
Johns Hopkins University School of Medicine, Baltimore, Maryland

Dennis W. Dickson, MD
Mayo Clinic, Jacksonville, Florida

Kurt Farrell, PhD
Icahn School of Medicine at Mount Sinai, New York, NY

Bess Frost, PhD
Brown University, Providence, RI

Jason Gestwicki, PhD
University of California, San Francisco, San Francisco, California

Günter U. Höglinger, MD
German Center for Neurodegenerative Diseases & Technical University Munich, Munich, Germany

Celeste Karch, PhD
Washington University School of Medicine, St. Louis, MO

Gabor Kovacs, MD, PhD
University of Toronto, Toronto, Ontario

Virginia M.-Y. Lee, PhD

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Irene Litvan, MD
University of California, San Diego, San Diego, California

Maura Malpetti, PhD
University of  Cambridge, Cambridge, UK

Huw R. Morris, PhD, FRCP
National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London, England

Amanda Woerman, PhD
Colorado State University, Fort Collins, CO